CLINICAL TRIAL

A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD)

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: ClinicalTrials.gov
Date: 2026-07-23
Source: ClinicalTrials.gov
DOI: Unavailable
PubMed: Unavailable

Authors

Usona Institute

Watch author

Derived topics and classifications

psilocybin Depression Safety Adverse Events Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Psychedelics and Psychotherapy: Is the Whole Greater than the Sum of its Parts?Clinical Pharmacology & Therapeutics · 2023-10-05 The Potential of Psilocybin Administration in Terminal Cancer PatientsOncology Times · 2019-06-28 Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial.BJPsych open · 2023-07-25 Safety, Tolerability, Outcomes of Psilocybin for Depression (STOP Depression) in Veterans With Spinal Cord InjuryClinicalTrials.gov · 2026-08-10 Efficacy of Psilocybin-Assisted Therapy in Major Depressive Disorder: A Systematic Review and Meta-AnalysisPsychiatry International · 2026-06-15 Efficacy and Safety of Psilocybin in Treatment-Resistant Major DepressionJAMA Psychiatry · 2026-05-01 PSILOCYBIN IN PSYCHIATRIC PRACTICE AND PSYCHEDELIC-ASSISTED THERAPY FOR TREATMENT-RESISTANT DEPRESSIONInternational Journal of Innovative Technologies in Social Science · 2026-01-28 The therapeutic efficacy of psilocybin in major depressive disorder: A review of recent clinical and mechanistic evidenceZenodo (CERN European Organization for Nuclear Research) · 2026-01-26